https://www.pharmaradar360.com/article/opus-genetics-aligns-with-fda-on-phase-3-trial-for-lca5-therapy-20b0af33bd10222bPharma Surgeen2026-07-06T11:20:05.000ZOpus Genetics aligns with FDA on Phase 3 trial for LCA5 therapyhttps://www.pharmaradar360.com/article/call-for-urgency-to-deliver-on-global-pledge-for-antibiotic-incentives-8410651fcfb2fb21Pharma Surgeen2026-07-06T11:17:46.000ZCall for urgency to deliver on global pledge for antibiotic incentiveshttps://www.pharmaradar360.com/article/abpi-welcome-the-appointment-of-sir-hugh-taylor-to-key-role-in-voluntary-scheme-39056310c3c2adaePharma Surgeen2026-07-06T11:17:24.000ZABPI welcome the appointment of Sir Hugh Taylor to key role in Voluntary Scheme negotiationshttps://www.pharmaradar360.com/article/abpi-response-to-mhra-clinical-trials-framework-e80894ced2632da3Pharma Surgeen2026-07-06T11:17:11.000ZABPI response to MHRA clinical trials frameworkhttps://www.pharmaradar360.com/article/novo-nordisk-is-suspended-from-abpi-membership-1915d3064720b506Pharma Surgeen2026-07-06T11:16:58.000ZNovo Nordisk is suspended from ABPI membershiphttps://www.pharmaradar360.com/article/abpi-response-to-the-budget-8187ce9f0eb61de7Pharma Surgeen2026-07-06T11:16:42.000ZABPI response to the Budgethttps://www.pharmaradar360.com/article/abpi-welcomes-new-nhs-research-guidance-c5e2fd624c5585f4Pharma Surgeen2026-07-06T11:16:02.000ZABPI welcomes new NHS research guidancehttps://www.pharmaradar360.com/article/susan-rienow-of-pfizer-confirmed-as-president-of-the-abpi-377b62fd55e5be7ePharma Surgeen2026-07-06T11:15:49.000ZSusan Rienow of Pfizer confirmed as President of the ABPIhttps://www.pharmaradar360.com/article/abpi-refreshes-its-commitment-to-improve-public-involvement-in-research-f8b745e29aa13989Pharma Surgeen2026-07-06T11:15:36.000ZABPI refreshes its commitment to improve public involvement in researchhttps://www.pharmaradar360.com/article/abpi-response-to-science-and-technology-framework-publication-4f734d0bc88504b7Pharma Surgeen2026-07-06T11:15:24.000ZABPI response to Science and Technology Framework publicationhttps://www.pharmaradar360.com/article/abpi-response-to-government-statutory-scheme-rise-6aabb67a1c1f3bc9Pharma Surgeen2026-07-06T11:15:13.000ZABPI response to government Statutory Scheme risehttps://www.pharmaradar360.com/article/veraxa-biotech-targets-2028-ind-filing-for-lead-candidate-by-investing-com-d31c4febc8681324Pharma Surgeen2026-07-06T11:15:05.000ZVERAXA Biotech targets 2028 IND filing for lead candidate By Investing.comhttps://www.pharmaradar360.com/article/abpi-sets-out-new-proposals-to-support-the-nhs-and-economic-growth-bca5067914b834dfPharma Surgeen2026-07-06T11:15:00.000ZABPI sets out new proposals to support the NHS and economic growthhttps://www.pharmaradar360.com/article/abpi-response-to-england-s-2023-rare-disease-action-plan-46a5f7b542ab8928Pharma Surgeen2026-07-06T11:14:45.000ZABPI response to England's 2023 Rare Disease Action Planhttps://www.pharmaradar360.com/article/abpi-respond-to-the-new-northern-ireland-brexit-deal-17ae367fd0c588a4Pharma Surgeen2026-07-06T11:14:33.000ZABPI respond to the new Northern Ireland Brexit dealhttps://www.pharmaradar360.com/article/abpi-response-to-lord-o-shaughnessy-review-a57f6318b9a47f70Pharma Surgeen2026-07-06T11:14:22.000ZABPI response to Lord O'Shaughnessy Reviewhttps://www.pharmaradar360.com/article/pharmaceutical-industry-a-key-player-in-scotland-s-life-sciences-sector-1ffd0289b998c626Pharma Surgeen2026-07-06T11:14:07.000ZPharmaceutical industry a key player in Scotland’s life sciences sectorhttps://www.pharmaradar360.com/article/pinder-sahota-to-step-down-as-abpi-president-0ab5281d383d86c6Pharma Surgeen2026-07-06T11:13:53.000ZPinder Sahota to step down as ABPI Presidenthttps://www.pharmaradar360.com/article/pharma-industry-urges-halt-to-further-rises-in-record-revenue-clawbacks-a0e7b04b37fac42bPharma Surgeen2026-07-06T11:13:40.000ZPharma industry urges halt to further rises in record revenue clawbackshttps://www.pharmaradar360.com/article/abpi-response-to-new-mhra-fees-announced-for-1-april-2023-c4fdd0ec41303cbcPharma Surgeen2026-07-06T11:13:27.000ZABPI response to new MHRA fees announced for 1 April 2023https://www.pharmaradar360.com/article/medicines-manufacturing-has-the-potential-to-drive-uk-growth-over-the-next-10-ye-11e87da082dd5d30Pharma Surgeen2026-07-06T11:13:11.000ZMedicines manufacturing has the potential to drive UK growth over the next 10 yearshttps://www.pharmaradar360.com/article/abpi-response-to-mhra-european-commission-decision-reliance-procedure-ecdrp-anno-b875935a72201f22Pharma Surgeen2026-07-06T11:13:00.000ZABPI response to MHRA European Commission Decision Reliance Procedure (ECDRP) announcementhttps://www.pharmaradar360.com/article/veraxa-biotech-ag-provides-pipeline-and-partnering-update-advances-bitac-develop-ee42babd2c9a876bPharma Surgeen2026-07-06T11:12:00.000ZVERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategyhttps://www.pharmaradar360.com/article/opus-genetics-reaches-fda-alignment-on-phase-3-design-for-opgx-lca5-bla-may-be-s-a7209b25c8151a6cPharma Surgeen2026-07-06T11:12:00.000ZOpus Genetics Reaches FDA Alignment on Phase 3 Design for OPGx-LCA5; BLA May Be Submitted Based on 6-Month Datahttps://www.pharmaradar360.com/article/invivyd-announces-receipt-of-twelve-months-advanced-notice-of-emergency-use-auth-c2a83c7978ea76d9Pharma Surgeen2026-07-06T11:08:15.000ZInvivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDAhttps://www.pharmaradar360.com/article/can-fite-nyse-american-canf-reaches-key-phase-3-psoriasis-interim-analysis-miles-8e5e833a964b01a8Pharma Surgeen2026-07-06T11:03:38.000ZCan-Fite (NYSE American: CANF) reaches key Phase 3 psoriasis interim analysis milestonehttps://www.pharmaradar360.com/article/pemgarda-faces-2027-eua-end-as-invivyd-talks-next-steps-with-fda-ea8b03d54596a588Pharma Surgeen2026-07-06T11:01:00.000ZPEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDAhttps://www.pharmaradar360.com/article/fda-accepts-pharvaris-nda-for-oral-hae-attack-treatment-drug-by-investing-com-ebefbc7c57bba31dPharma Surgeen2026-07-06T11:00:03.000ZFDA accepts Pharvaris NDA for oral HAE attack treatment drug By Investing.comhttps://www.pharmaradar360.com/article/belite-bio-takes-phase-3-stargardt-disease-data-to-two-eye-meetings-3a40c685b2536738Pharma Surgeen2026-07-06T11:00:00.000ZBelite Bio takes Phase 3 Stargardt disease data to two eye meetingshttps://www.pharmaradar360.com/article/can-fite-s-psoriasis-study-reaches-interim-analysis-after-247-patients-enrolled-2d2c99ffafabf338Pharma Surgeen2026-07-06T11:00:00.000ZCan-Fite’s psoriasis study reaches interim analysis after 247 patients enrolledhttps://www.pharmaradar360.com/article/opus-genetics-clears-fda-design-for-phase-3-trial-in-childhood-blindness-32e9e777f25a5955Pharma Surgeen2026-07-06T11:00:00.000ZOpus Genetics clears FDA design for Phase 3 trial in childhood blindnesshttps://www.pharmaradar360.com/article/veraxa-says-its-bitac-cancer-pipeline-is-drawing-partner-interest-5e5daa943376e675Pharma Surgeen2026-07-06T11:00:00.000ZVERAXA says its BiTAC cancer pipeline is drawing partner interesthttps://www.pharmaradar360.com/article/can-fite-achieves-key-pivotal-phase-3-psoriasis-milestone-with-completion-of-pat-7b17e29fb7858796Pharma Surgeen2026-07-06T11:00:00.000ZCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027https://www.pharmaradar360.com/article/ionis-completes-enrollment-in-pivotal-cohort-of-the-phase-3-reveal-study-evaluat-d27c4fb074a833a7Pharma Surgeen2026-07-06T11:00:00.000ZIonis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndromehttps://www.pharmaradar360.com/article/pharvaris-announces-fda-acceptance-of-nda-for-deucrictibant-ir-capsule-for-on-de-5d9a196c6312ea2ePharma Surgeen2026-07-06T11:00:00.000ZPharvaris Announces FDA Acceptance of NDA for Deucrictibant IR Capsule for On-Demand Treatment of HAE Attackshttps://www.pharmaradar360.com/article/pharvaris-wins-fda-review-for-oral-hae-attack-treatment-3314d800712b5914Pharma Surgeen2026-07-06T10:50:00.000ZPharvaris wins FDA review for oral HAE attack treatmenthttps://www.pharmaradar360.com/article/swiss-drugmaker-novartis-buys-uk-biotech-firm-in-1-5bn-deal-19b02ea12f163d29Pharma Surgeen2026-07-06T10:49:15.000ZSwiss drugmaker Novartis buys UK biotech firm in $1.5bn dealhttps://www.pharmaradar360.com/article/maharashtra-fda-tightens-milk-safety-rules-7039750cf431b278Pharma Surgeen2026-07-06T10:48:18.000ZMaharashtra FDA tightens milk safety ruleshttps://www.pharmaradar360.com/article/maharashtra-fda-flags-three-beauty-creams-over-toxic-mercury-and-lead-levels-e704186be85e7b80Pharma Surgeen2026-07-06T10:20:45.000ZMaharashtra FDA flags three beauty creams over toxic mercury and lead levelshttps://www.pharmaradar360.com/article/nhs-sets-first-ever-staff-standards-to-tackle-racism-and-violence-12a37bcb5ba604c4Pharma Surgeen2026-07-06T10:13:19.000ZNHS sets first-ever staff standards to tackle racism and violencehttps://www.pharmaradar360.com/article/ataibeckley-announces-last-patient-dosed-in-phase-2b-elumina-trial-of-vls-01-for-639f4cd3193a7147Pharma Surgeen2026-07-06T10:11:00.000ZAtaiBeckley Announces Last Patient Dosed in Phase 2b Elumina Trial of VLS-01 for Treatment-Resistant Depression; Topline Data Expected in Q4 2026https://www.pharmaradar360.com/article/immuron-advances-imm-529-clostridioides-difficile-infection-partnering-strategy-ea876d4d4ce778c8Pharma Surgeen2026-07-06T10:07:09.000ZImmuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategyhttps://www.pharmaradar360.com/article/reshoring-pharma-and-biotech-manufacturing-ahead-of-this-summer-s-tariff-deadlin-6b32118f49560292Pharma Surgeen2026-07-06T10:02:27.000ZReshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Lasthttps://www.pharmaradar360.com/article/should-dayquil-be-legal-6ed5ddb208bb649ePharma Surgeen2026-07-06T10:02:21.000ZShould DayQuil be legal?https://www.pharmaradar360.com/article/toxic-fairness-creams-linked-to-kidney-disease-in-18-women-6878c877e955907bPharma Surgeen2026-07-06T10:01:16.000ZToxic Fairness Creams Linked to Kidney Disease in 18 Womenhttps://www.pharmaradar360.com/article/immuron-seeks-partner-for-gut-infection-drug-imm-529-c7b751e144b4b4f0Pharma Surgeen2026-07-06T10:00:00.000ZImmuron seeks partner for gut infection drug IMM-529https://www.pharmaradar360.com/article/a-decade-in-deals-houston-biotech-vc-deals-gradually-increasing-after-ups-and-do-fe3f0df4454cdd87Pharma Surgeen2026-07-06T10:00:00.000ZA decade in deals: Houston biotech VC deals gradually increasing after ups and downshttps://www.pharmaradar360.com/article/alzheon-to-present-new-evidence-of-neurovascular-protection-and-preserved-brain-8c2939d28114cbcaPharma Surgeen2026-07-06T10:00:00.000ZAlzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in Londonhttps://www.pharmaradar360.com/article/5-biotech-stocks-that-delivered-100-to-300-gains-did-your-winning-trades-offset-d034e442512d022bPharma Surgeen2026-07-06T09:51:00.000Z5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?https://www.pharmaradar360.com/article/departmental-minute-on-public-dividend-capital-write-off-2025-to-2026-e362405845de73d3Pharma Surgeen2026-07-06T09:46:09.000ZDepartmental minute on public dividend capital write-off: 2025 to 2026https://www.pharmaradar360.com/article/newsletter-20-df9bc8c342e9de8fPharma Surgeen2026-07-06T09:38:22.000ZNewsletter #20https://www.pharmaradar360.com/article/germany-modifies-healthcare-reforms-to-ease-burden-on-pharma-3b31af9ccf0c0d7cPharma Surgeen2026-07-06T09:23:49.000ZGermany Modifies Healthcare Reforms to Ease Burden on Pharmahttps://www.pharmaradar360.com/article/maharashtra-fda-mandates-free-potable-water-in-all-hotels-and-restaurants-1179372d18636427Pharma Surgeen2026-07-06T09:12:43.000ZMaharashtra FDA Mandates Free Potable Water in All Hotels and Restaurantshttps://www.pharmaradar360.com/article/novartis-to-pay-1-1b-upfront-for-myricx-to-expand-adc-pipeline-30acd7817780d25aPharma Surgeen2026-07-06T09:10:00.000ZNovartis to pay $1.1B upfront for Myricx to expand ADC pipelinehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-edesa-biotech-inc-nasdaq-edsa-0b3a9b3f40ef48ccPharma Surgeen2026-07-06T09:05:52.000ZEnterprise value to EBIT forward of Edesa Biotech, Inc. – NASDAQ:EDSAhttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-c40ee43363d9a479Pharma Surgeen2026-07-06T09:00:02.000ZMeningococcal B (MenB) time limited vaccination offerhttps://www.pharmaradar360.com/article/how-evogene-is-changing-the-future-for-the-pharma-and-agriculture-markets-5efe6d7c986d8dc6Pharma Surgeen2026-07-06T08:57:31.000ZHow Evogene is changing the future for the pharma and agriculture marketshttps://www.pharmaradar360.com/article/korea-pharma-biotech-stocks-head-for-event-driven-second-half-a2cc44035f1cfa5dPharma Surgeen2026-07-06T08:54:44.000ZKorea Pharma, Biotech Stocks Head for Event-Driven Second Halfhttps://www.pharmaradar360.com/article/i-spoke-to-anthropic-s-ceo-about-how-ai-may-affect-biotech-here-s-what-i-learned-9fad86120fd8512ePharma Surgeen2026-07-06T08:33:59.000ZI spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learnedhttps://www.pharmaradar360.com/article/zhejiang-conba-pharmaceutical-s-subsidiaries-sign-licensing-agreement-with-adneu-7fb287f36e3d745bPharma Surgeen2026-07-06T08:32:59.000ZZhejiang CONBA Pharmaceutical's Subsidiaries Sign Licensing Agreement With Adneurishttps://www.pharmaradar360.com/article/greater-bay-area-emerges-as-launchpad-for-china-s-biotech-rise-a0ff1a14c3c11672Pharma Surgeen2026-07-06T08:31:10.000ZGreater Bay Area emerges as launchpad for China's biotech risehttps://www.pharmaradar360.com/article/nhs-staff-standards-bb9d2a72502e72d3Pharma Surgeen2026-07-06T08:30:06.000ZNHS staff standardshttps://www.pharmaradar360.com/article/novartis-buys-uk-adc-biotech-myricx-bio-in-up-to-1-5bn-deal-5a88d5fca3fe183cPharma Surgeen2026-07-06T08:23:23.000ZNovartis buys UK ADC biotech Myricx Bio in up to $1.5bn dealhttps://www.pharmaradar360.com/article/price-to-book-forward-of-beijing-beilu-pharmaceutical-co-ltd-class-a-szse-300016-f708a92f2d348cc1Pharma Surgeen2026-07-06T08:07:51.000ZPrice to book forward of Beijing Beilu Pharmaceutical Co., Ltd. Class A – SZSE:300016https://www.pharmaradar360.com/article/maharashtra-fda-orders-recall-of-pak-origin-goree-fairness-creams-two-others-ove-9c973f588155b31dPharma Surgeen2026-07-06T07:57:26.000ZMaharashtra FDA orders recall of Pak-origin Goree fairness creams, two others over toxic mercury, lead levelshttps://www.pharmaradar360.com/article/elevation-point-wealth-partners-llc-makes-new-1-33-million-investment-in-teva-ph-00528a127c4a505aPharma Surgeen2026-07-06T07:55:31.000ZElevation Point Wealth Partners LLC Makes New $1.33 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-4916613f488c7a16Pharma Surgeen2026-07-06T07:48:54.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/novartis-to-buy-uk-biotech-myricx-bio-in-1-5bn-deal-ab3db980af7aeca2Pharma Surgeen2026-07-06T07:46:19.000ZNovartis to buy UK biotech Myricx Bio in $1.5bn dealhttps://www.pharmaradar360.com/article/celltrion-files-amendment-for-u-s-phase-3-trial-of-keytruda-biosimilar-ct-p51-7e387284880d63f6Pharma Surgeen2026-07-06T07:44:51.000ZCelltrion Files Amendment for U.S. Phase 3 Trial of Keytruda Biosimilar CT-P51https://www.pharmaradar360.com/article/48-trillion-won-keytruda-biosimilar-race-heats-up-b1553a6b11b9e1dfPharma Surgeen2026-07-06T07:41:49.000Z48 Trillion Won Keytruda Biosimilar Race Heats Uphttps://www.pharmaradar360.com/article/algenomics-ceo-sungwook-lee-invited-as-speaker-at-rna-symposium-and-global-bio-c-8d702931f32cc8bcPharma Surgeen2026-07-06T07:33:33.000ZAlgenomics CEO Sungwook Lee Invited as Speaker at RNA Symposium and Global Bio Conferencehttps://www.pharmaradar360.com/article/ai-is-transforming-drug-discovery-here-is-the-next-trillion-dollar-biotech-oppor-a5e37ce75ab9c101Pharma Surgeen2026-07-06T07:30:27.000ZAI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunityhttps://www.pharmaradar360.com/article/statement-on-pabs-instrument-at-the-seventh-meeting-of-the-intergovernmental-wor-eaaaa465dccea49aPharma Surgeen2026-07-06T07:29:13.000ZStatement on PABS Instrument at the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreementhttps://www.pharmaradar360.com/article/travere-therapeutics-wins-much-awaited-approval-for-drug-in-rare-kidney-disease-1174c8bccb244c2aPharma Surgeen2026-07-06T07:06:30.000ZTravere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Diseasehttps://www.pharmaradar360.com/article/nicox-s-ncx-470-new-drug-application-submitted-in-the-united-states-by-kowa-5fe07132926e4969Pharma Surgeen2026-07-06T07:02:57.000ZNicox’s NCX 470 new drug application submitted in the United States by Kowahttps://www.pharmaradar360.com/article/cannabis-formula-granted-breakthrough-therapy-designation-by-fda-for-pain-treatm-38ed0166ea37a68dPharma Surgeen2026-07-06T07:02:02.000ZCannabis Formula Granted "Breakthrough Therapy Designation" by FDA for Pain Treatmenthttps://www.pharmaradar360.com/article/otsuka-pharmaceutical-s-subsidiary-astex-enters-exclusive-research-collaboration-2a45c2feee865884Pharma Surgeen2026-07-06T07:00:00.000ZOtsuka Pharmaceutical's Subsidiary Astex Enters Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Programhttps://www.pharmaradar360.com/article/the-geroscience-biomarker-gap-why-immune-aging-endpoints-are-about-to-reshape-tr-94b04b8b6422293bPharma Surgeen2026-07-06T06:53:53.000ZThe Geroscience Biomarker Gap: Why Immune Aging Endpoints Are About to Reshape Trial Designhttps://www.pharmaradar360.com/article/futura-medical-new-us-eroxon-deal-and-positive-wsd4000-women-s-health-data-d6ddbf54c7aa64d0Pharma Surgeen2026-07-06T06:28:34.000ZFutura Medical: new US Eroxon deal and positive WSD4000 women's health datahttps://www.pharmaradar360.com/article/abivax-stock-surges-on-obefazimod-safety-data-cancer-concerns-cd9bcda14ba29638Pharma Surgeen2026-07-06T06:27:44.000ZAbivax stock surges on obefazimod safety data, cancer concernshttps://www.pharmaradar360.com/article/pune-fda-shuts-down-mathura-pure-veg-temporarily-over-food-safety-violations-d5d40274f036558bPharma Surgeen2026-07-06T06:26:55.000ZPune: FDA Shuts Down Mathura Pure Veg Temporarily Over Food Safety Violationshttps://www.pharmaradar360.com/article/glenmark-pharma-jumps-over-2-on-launch-of-olanzapine-single-dose-vial-c04486885cb3a13bPharma Surgeen2026-07-06T06:11:16.000ZGlenmark Pharma jumps over 2% on launch of Olanzapine single-dose vialhttps://www.pharmaradar360.com/article/lotte-chairman-declares-biotech-a-new-core-business-49ca2d9f080ffa58Pharma Surgeen2026-07-06T06:03:00.000ZLotte chairman declares biotech a new core businesshttps://www.pharmaradar360.com/article/draft-for-comments-amendment-to-fda-circular-no-2025-001-entitled-guidelines-on-3da59bfe76812191Pharma Surgeen2026-07-06T06:00:41.000ZDraft for Comments || Amendment to FDA Circular No. 2025-001 entitled “Guidelines on the Classification of Vitamins and Minerals for Food/Dietary Supplements for Adults under Processed Food Product, Repealing the Level Set for Food in the Office Order Nhttps://www.pharmaradar360.com/article/mah-fda-warns-against-3-beauty-creams-after-tests-detect-excessive-mercury-lead-e450c39945bcbc34Pharma Surgeen2026-07-06T05:56:01.000ZMah FDA warns against 3 beauty creams after tests detect excessive mercury, leadhttps://www.pharmaradar360.com/article/black-diamond-therapeutics-positive-phase-2-results-offer-an-upside-nasdaq-bdtx-d3f29596e7181706Pharma Surgeen2026-07-06T05:51:02.000ZBlack Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX)https://www.pharmaradar360.com/article/what-nppa-s-renewed-focus-on-form-iii-reporting-means-for-pharmaceutical-compani-36737f32519f6bf6Pharma Surgeen2026-07-06T05:43:03.000ZWhat NPPA's Renewed Focus on Form III Reporting Means for Pharmaceutical Companieshttps://www.pharmaradar360.com/article/aussie-super-funds-hit-the-jackpot-in-2b-uk-biotech-deal-20bb6235a8782258Pharma Surgeen2026-07-06T05:38:00.000ZAussie super funds hit the jackpot in $2b UK biotech dealhttps://www.pharmaradar360.com/article/cash-per-share-of-gin-hwa-biotech-inc-tpex-7806-b120a5be5e9ae743Pharma Surgeen2026-07-06T05:29:09.000ZCash per share of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/will-these-upcoming-milestones-re-rate-the-stock-ac86981f32544d60Pharma Surgeen2026-07-06T05:19:08.000ZWill These Upcoming Milestones Re-rate The Stock?https://www.pharmaradar360.com/article/china-hk-stocks-gain-as-ai-enthusiasm-broadens-to-farming-biotech-sectors-bc64b39ec0deee35Pharma Surgeen2026-07-06T04:43:20.000ZChina, HK stocks gain as AI enthusiasm broadens to farming, biotech sectorshttps://www.pharmaradar360.com/article/positive-phase-2-results-for-new-oral-glp-1-for-obesity-591f4b2f1456e1d1Pharma Surgeen2026-07-06T04:35:17.000ZPositive Phase 2 Results for New Oral GLP-1 for Obesityhttps://www.pharmaradar360.com/article/opinion-the-fda-must-put-biotech-at-its-center-or-continue-to-cede-early-researc-ed9c9fa4d0b70a2bPharma Surgeen2026-07-06T04:25:58.000ZOpinion: The FDA must put biotech at its center or continue to cede early research to Chinahttps://www.pharmaradar360.com/article/despite-chaos-and-churn-fda-decisions-hold-mostly-steady-in-h1-2026-4b2bc0f527ba9fd1Pharma Surgeen2026-07-06T04:05:57.000ZDespite chaos and churn, FDA decisions hold mostly steady in H1 2026https://www.pharmaradar360.com/article/triple-digit-gains-haven-t-killed-this-biotech-s-upside-here-s-what-comes-next-aa1124c7403c971fPharma Surgeen2026-07-06T04:02:30.000ZTriple-Digit Gains Haven’t Killed This Biotech’s Upside. Here’s What Comes Nexthttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-is-up-5-3-after-new-insilico-ai-drug-discovery-de-c4902bf81718f89fPharma Surgeen2026-07-06T03:37:09.000ZTakeda Pharmaceutical (TSE:4502) Is Up 5.3% After New Insilico AI Drug Discovery Deal - Has The Bull Case Changed?https://www.pharmaradar360.com/article/etfs-investing-in-takeda-pharmaceutical-co-ltd-sponsored-adr-stocks-3b861f7d475c5711Pharma Surgeen2026-07-06T03:17:50.000ZETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stockshttps://www.pharmaradar360.com/article/shinsa-software-as-a-medical-device-samd-page-updated-8fd558e9473c46f8Pharma Surgeen2026-07-06T03:00:00.000Z[SHINSA]Software as a Medical Device (SaMD) page updatedhttps://www.pharmaradar360.com/article/bulgaria-moves-to-shore-up-generic-medicines-access-amid-shortage-crisis-a7869e4b2ddd5bd2Pharma Surgeen2026-07-06T00:57:34.000ZBulgaria moves to shore up generic medicines access amid shortage crisishttps://www.pharmaradar360.com/article/startup-island-taiwan-bridges-tech-hubs-launching-east-coast-biotech-initiative-f66c47affdedadcaPharma Surgeen2026-07-06T00:27:00.000ZStartup Island TAIWAN Bridges Tech Hubs, Launching East Coast Biotech Initiative in Bostonhttps://www.pharmaradar360.com/article/revolution-medicines-is-up-nearly-140-in-2026-is-the-hot-biotech-stock-still-a-b-93d330af38b11c76Pharma Surgeen2026-07-06T00:15:00.000ZRevolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?https://www.pharmaradar360.com/article/regeneron-filed-form-8-k-794be60927f29c49Pharma Surgeen2026-07-06T00:00:00.000ZRegeneron filed Form 8-Khttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-7996769044e442e1Pharma Surgeen2026-07-06T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-32c6c53e7a0ca514Pharma Surgeen2026-07-06T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-5842b2375b7eca30Pharma Surgeen2026-07-06T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-8eb0bf92d1ae2f4fPharma Surgeen2026-07-06T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-948222f1b88b0028Pharma Surgeen2026-07-06T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-d002e7cc25c4e109Pharma Surgeen2026-07-06T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-706a71e62515d0a5Pharma Surgeen2026-07-06T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-fa51638b6af55ea6Pharma Surgeen2026-07-06T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-9b3c1428472b8eddPharma Surgeen2026-07-06T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-19a412ba063fce2dPharma Surgeen2026-07-06T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-d742ebe57b8b944ePharma Surgeen2026-07-06T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-b32f42492b21eab2Pharma Surgeen2026-07-06T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-3c1043f1a117e42ePharma Surgeen2026-07-06T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-53db95eaaf94cec2Pharma Surgeen2026-07-06T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-e7df32506d97c64ePharma Surgeen2026-07-06T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-7d2cc969f2df410bPharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/endo-operations-limited-et-al-withdrawal-of-approval-of-34-new-drug-applications-0fe04ab6d448b9fcPharma Surgeen2026-07-06T00:00:00.000ZEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applicationshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-199f19173a542002Pharma Surgeen2026-07-06T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/temporary-placement-of-7-hydroxymitragynine-above-a-specified-threshold-in-sched-92546f760ae2e0f2Pharma Surgeen2026-07-06T00:00:00.000ZTemporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Informationhttps://www.pharmaradar360.com/article/patient-safety-organizations-voluntary-relinquishment-for-the-cassatt-patient-sa-6766b6300bea36dfPharma Surgeen2026-07-06T00:00:00.000ZPatient Safety Organizations: Voluntary Relinquishment for the Cassatt Patient Safety Organizationhttps://www.pharmaradar360.com/article/calendar-year-2027-home-health-prospective-payment-system-hh-pps-rate-update-req-3a9334c892e48d51Pharma Surgeen2026-07-06T00:00:00.000ZCalendar Year 2027 Home Health Prospective Payment System (HH PPS) Rate Update; Requirements for the HH Quality Reporting Program and the Expanded HH Value-Based Purchasing Model; Medicare Provider Enrollment, Durable Medical Equipment (DME), and DME, Prosthetics, Orthotics, and Supplies (DMEPOS) Pohttps://www.pharmaradar360.com/article/expedited-investigational-new-drug-pilot-program-request-for-information-correct-2513bdc5da3cf1e1Pharma Surgeen2026-07-06T00:00:00.000ZExpedited Investigational New Drug Pilot Program; Request for Information; Correctionhttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-generic-clearance-for-nih-citizen-sci-f5ec33c9d6a787e9Pharma Surgeen2026-07-06T00:00:00.000ZProposed Collection; 60-day Comment Request; Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (Office of the Director)https://www.pharmaradar360.com/article/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindo-1aa191820c019a08Pharma Surgeen2026-07-06T00:00:00.000ZSchedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule Ihttps://www.pharmaradar360.com/article/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-ab-eabb6b75cd05a680Pharma Surgeen2026-07-06T00:00:00.000ZSchedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule Ihttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-360d8559fb466d0dPharma Surgeen2026-07-06T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-2a64b20c2642d6d5Pharma Surgeen2026-07-06T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-4298c7d56bd0f39fPharma Surgeen2026-07-06T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-c32590e3f5bd7295Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearingshttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-bio-c4bbe26b4f6c5b34Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirementshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-3f7ab81c9f30ed02Pharma Surgeen2026-07-06T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Deviceshttps://www.pharmaradar360.com/article/determination-that-vasopressin-in-sodium-chloride-vasopressin-0-9-injection-50-u-c7aba6861bc2d564Pharma Surgeen2026-07-06T00:00:00.000ZDetermination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/le-quebec-est-la-premiere-province-a-inscrire-pr-okedi-md-suspension-injectable-02134888f0ad8056Pharma Surgeen2026-07-06T00:00:00.000ZLe Québec est la première province à inscrire Pr OKEDI MD (suspension injectable à libération prolongée de rispéridone) sur la liste des médicaments remboursés par le régime public pour le traitement de la schizophréniehttps://www.pharmaradar360.com/article/quebec-is-the-first-province-to-list-pr-okedi-mc-extended-release-injectable-sus-5b3d15320f0ea413Pharma Surgeen2026-07-06T00:00:00.000ZQuébec is the first province to list Pr OKEDI MC (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophreniahttps://www.pharmaradar360.com/article/oropharyngeal-dysphagia-and-gastroesophageal-reflux-disease-in-lung-transplant-p-90c777494cce8317Pharma Surgeen2026-07-06T00:00:00.000ZOropharyngeal dysphagia and gastroesophageal reflux disease in lung transplant patients: a systematic review and meta-analysis of incidence, risk factors, and clinical outcomeshttps://www.pharmaradar360.com/article/abc-will-trial-using-ai-for-journalism-what-are-the-risks-and-benefits-526d7c54b00391e3Pharma Surgeen2026-07-06T00:00:00.000ZABC will trial using AI for journalism. What are the risks and benefits?https://www.pharmaradar360.com/article/peer-review-report-for-the-institutional-black-box-of-friction-between-digital-a-61c4d9388715100dPharma Surgeen2026-07-06T00:00:00.000ZPeer Review Report For: The Institutional Black Box of Friction Between Digital Agility Demands and Clinical Bureaucracy in Hospital Social Media Management [version 2; peer review: 2 approved]https://www.pharmaradar360.com/article/choline-pet-ct-in-the-psma-era-clinical-repositioning-biological-perspectives-an-f8d89fc97513b334Pharma Surgeen2026-07-06T00:00:00.000ZCholine PET/CT in the PSMA Era: Clinical Repositioning, Biological Perspectives, and Emerging Applicationshttps://www.pharmaradar360.com/article/clinical-efficacy-of-stmipo-in-the-management-of-distal-one-third-fibular-fractu-df5e94b1987e5b96Pharma Surgeen2026-07-06T00:00:00.000ZClinical efficacy of STMIPO in the management of distal one-third fibular fractureshttps://www.pharmaradar360.com/article/association-between-urea-to-creatinine-ratio-trajectories-and-clinical-outcomes-f71949fe6777b9f7Pharma Surgeen2026-07-06T00:00:00.000ZAssociation between urea-to-creatinine ratio trajectories and clinical outcomes in chronic critical illness patients: a retrospective cohort studyhttps://www.pharmaradar360.com/article/a-novel-optimized-surgical-strategy-for-secondary-hyperparathyroidism-clean-para-10f5594b85301407Pharma Surgeen2026-07-06T00:00:00.000ZA novel optimized surgical strategy for secondary hyperparathyroidism: clean parathyroidectomy combined with autotransplantation and its clinical analysishttps://www.pharmaradar360.com/article/effectiveness-of-occupational-therapy-handwriting-interventions-for-preschoolers-0a340233f477482dPharma Surgeen2026-07-06T00:00:00.000ZEffectiveness of occupational-therapy handwriting interventions for Preschoolers (Age Group 4–6)https://www.pharmaradar360.com/article/assessment-of-knowledge-attitude-and-practices-regarding-prevention-of-catheter-ffe3f7a7a54e2421Pharma Surgeen2026-07-06T00:00:00.000ZAssessment of Knowledge, Attitude, and Practices Regarding Prevention of Catheter-Associated Urinary Tract Infections Among Nursing Staff: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/development-of-stratum-corneum-lipid-liposomes-for-topical-drug-delivery-5da47dc922289b31Pharma Surgeen2026-07-06T00:00:00.000ZDevelopment of Stratum Corneum Lipid Liposomes for Topical Drug Deliveryhttps://www.pharmaradar360.com/article/effect-of-different-doses-of-ondansetron-on-hemodynamic-status-in-patients-under-bc4caeb4bee60292Pharma Surgeen2026-07-06T00:00:00.000ZEffect of Different Doses of Ondansetron on Hemodynamic Status in Patients Undergoing Elective Caesarean Section Under Spinal Anaesthesia: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/index-e2c2f0a7774ed808Pharma Surgeen2026-07-06T00:00:00.000ZIndexhttps://www.pharmaradar360.com/article/979-effects-of-primary-tumor-and-its-ablation-on-the-growth-of-metastases-a-natu-7582c2f49f7609eePharma Surgeen2026-07-06T00:00:00.000Z979 Effects of primary tumor and its ablation on the growth of metastases: a natural lawhttps://www.pharmaradar360.com/article/747-the-laws-of-tumor-growth-c04d55320e9d4fa7Pharma Surgeen2026-07-06T00:00:00.000Z747 The laws of tumor growthhttps://www.pharmaradar360.com/article/monitorizacion-de-concentraciones-sericas-de-abiraterona-bf99eb88c512c768Pharma Surgeen2026-07-06T00:00:00.000ZMonitorización de concentraciones séricas de abirateronahttps://www.pharmaradar360.com/article/i-de-novo-arid1a-i-coffin-siris-syndrome-with-hypothyroidism-and-dyslipidemia-a-c1faeaa47e1f0c5bPharma Surgeen2026-07-06T00:00:00.000Z<i>De novo ARID1A</i> Coffin-Siris syndrome with hypothyroidism and dyslipidemia: A case report and literature reviewhttps://www.pharmaradar360.com/article/comparative-clinical-effectiveness-safety-and-cost-effectiveness-of-intravenous-990f8b734c66b833Pharma Surgeen2026-07-06T00:00:00.000ZComparative Clinical Effectiveness, Safety, and Cost-Effectiveness of Intravenous Tramadol versus Metamizole for Post-Procedural Pain Managementhttps://www.pharmaradar360.com/article/integration-of-genetic-evidence-to-identify-approved-drug-targets-0d9e59bb7356f437Pharma Surgeen2026-07-06T00:00:00.000ZIntegration of genetic evidence to identify approved drug targetshttps://www.pharmaradar360.com/article/virtual-reality-simulation-for-chemotherapy-drug-spill-management-training-in-ph-2f2cf8343adc9b44Pharma Surgeen2026-07-06T00:00:00.000ZVirtual reality simulation for chemotherapy drug spill management training in pharmacy education: A cohort-allocated crossover quasi-experimental study in Taiwanhttps://www.pharmaradar360.com/article/effects-of-tablet-based-augmented-reality-on-anxiety-fear-and-pain-during-venipu-5961a1fa33df4693Pharma Surgeen2026-07-06T00:00:00.000ZEffects of tablet-based augmented reality on anxiety, fear, and pain during venipuncture in children: a randomized controlled trialhttps://www.pharmaradar360.com/article/comprehensive-effects-of-occupational-therapy-using-ayres-sensory-integration-in-3134bec39f4bddd5Pharma Surgeen2026-07-06T00:00:00.000ZComprehensive Effects of Occupational Therapy Using Ayres Sensory Integration® in Children With ADHD: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/data-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-lt-i-gt-exon-18-mu-e86b0b68c01cc4afPharma Surgeen2026-07-06T00:00:00.000ZData from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/figure-4-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-lt-i-gt-exon-1-87ebc7ca9583b025Pharma Surgeen2026-07-06T00:00:00.000ZFigure 4 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/supp-fig-2-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-lt-i-gt-exon-400494a6b026df3aPharma Surgeen2026-07-06T00:00:00.000ZSupp. Fig. 2 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/supp-fig-7-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-lt-i-gt-exon-729354e0b18125ffPharma Surgeen2026-07-06T00:00:00.000ZSupp. Fig. 7 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/supplementary-table-s2-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-d17abb5088d685ddPharma Surgeen2026-07-06T00:00:00.000ZSupplementary Table S2 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/supplementary-table-s5-from-predicting-clinical-sensitivities-of-lt-i-gt-pdgfra-bffa5c12b1d78905Pharma Surgeen2026-07-06T00:00:00.000ZSupplementary Table S5 from Predicting Clinical Sensitivities of &lt;i&gt;PDGFRA&lt;/i&gt; Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatmenthttps://www.pharmaradar360.com/article/the-69th-session-of-the-un-commission-on-narcotic-drugs-multilateral-drug-policy-8f999d9aab89dc87Pharma Surgeen2026-07-06T00:00:00.000ZThe 69th session of the UN Commission on Narcotic Drugs: multilateral drug policy navigating fragmentationhttps://www.pharmaradar360.com/article/surface-eeg-to-identify-cognitive-motor-dissociation-after-acute-brain-injury-4aa5c4cddaf2f337Pharma Surgeen2026-07-06T00:00:00.000ZSurface EEG to Identify Cognitive Motor Dissociation After Acute Brain Injuryhttps://www.pharmaradar360.com/article/recommendations-for-assessing-methodological-quality-in-systematic-reviews-of-po-61aa75ef3db5046cPharma Surgeen2026-07-06T00:00:00.000ZRecommendations for Assessing Methodological Quality in Systematic Reviews of Population Pharmacokinetic Models: A Systematic Reviewhttps://www.pharmaradar360.com/article/exercise-testing-in-contemporary-aortic-stenosis-management-translating-pathophy-8a05f8468bf3ee80Pharma Surgeen2026-07-06T00:00:00.000ZExercise testing in contemporary aortic stenosis management: translating pathophysiological insights into clinical decision-makinghttps://www.pharmaradar360.com/article/effect-of-early-skin-to-skin-contact-after-vaginal-birth-on-neonatal-stress-and-1784d183bfb990f1Pharma Surgeen2026-07-06T00:00:00.000ZEffect of early skin-to-skin contact after vaginal birth on neonatal stress and day-5 bilirubin levels: a randomized trialhttps://www.pharmaradar360.com/article/orelabrutinib-versus-chemoimmunotherapy-in-treatment-naive-chronic-lymphocytic-l-7a52382412224fc0Pharma Surgeen2026-07-06T00:00:00.000ZOrelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trialhttps://www.pharmaradar360.com/article/analysis-of-the-effectiveness-of-injection-based-minimally-invasive-treatment-fo-9d1db97586700775Pharma Surgeen2026-07-06T00:00:00.000ZAnalysis of the Effectiveness of Injection-Based Minimally Invasive Treatment for Piriformis Syndrome: Clinical Outcomes and Anatomical Correlateshttps://www.pharmaradar360.com/article/developmental-trajectories-in-young-autistic-children-receiving-parent-mediated-2bd0319e048f0758Pharma Surgeen2026-07-06T00:00:00.000ZDevelopmental Trajectories in Young Autistic Children Receiving Parent-Mediated Intervention Through In-Person and Telehealth Service Delivery Models: A Naturalistic, Nonrandomized Clinical Studyhttps://www.pharmaradar360.com/article/cutaneous-lesions-with-cryptococcus-like-changes-in-the-context-of-anca-vasculit-6ebccf988ddd45fdPharma Surgeen2026-07-06T00:00:00.000ZCutaneous lesions with Cryptococcus-like changes in the context of ANCA vasculitis: case reports and literature reviewhttps://www.pharmaradar360.com/article/perinatal-mental-health-issues-in-consultations-regarding-medication-use-during-20b158ac4aa3d606Pharma Surgeen2026-07-06T00:00:00.000ZPerinatal mental health issues in consultations regarding medication use during breastfeeding: Insights from the Japan Drug Information Institute in Pregnancy (JDIIP)https://www.pharmaradar360.com/article/the-use-of-pharmacodynamic-results-for-recommended-phase-ii-decision-making-in-o-937cc22e28152489Pharma Surgeen2026-07-06T00:00:00.000ZThe use of pharmacodynamic results for recommended phase II decision making in oncology clinical trialshttps://www.pharmaradar360.com/article/anticipated-online-harassment-and-potential-chilling-effects-on-mandatory-child-b20e51e2146a2838Pharma Surgeen2026-07-06T00:00:00.000ZAnticipated online harassment and potential chilling effects on mandatory child abuse reporting: A pilot survey of pediatricians in Japanhttps://www.pharmaradar360.com/article/optimizing-integrated-multienzyme-membrane-system-to-maximize-xylo-oligosacchari-6749eab588c10a55Pharma Surgeen2026-07-06T00:00:00.000ZOptimizing integrated multienzyme‐membrane system to maximize xylo‐oligosaccharide yield and eradicate inhibitors: addressing fouling and sugar purification in pineapple residue processinghttps://www.pharmaradar360.com/article/abvx-stock-rockets-28-after-abivax-eases-drug-safety-concerns-with-fresh-clinica-0b3a00b0753a7019Pharma Surgeen2026-07-05T23:01:32.000ZABVX Stock Rockets 28% After Abivax Eases Drug Safety Concerns With Fresh Clinical Datahttps://www.pharmaradar360.com/article/united-parcel-service-inc-ups-eyes-medicines-and-pharmaceutical-opportunities-wi-2cd2af5be164263dPharma Surgeen2026-07-05T22:51:47.000ZUnited Parcel Service, Inc. (UPS) Eyes Medicines and Pharmaceutical Opportunities with $48M Investmenthttps://www.pharmaradar360.com/article/mbrx-stock-drops-25-as-moleculin-biotech-s-interim-cancer-trial-data-falls-short-d8f025f87aa6b36fPharma Surgeen2026-07-05T22:46:35.000ZMBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significancehttps://www.pharmaradar360.com/article/editorial-independent-drug-approvals-are-key-to-hong-kong-s-biotech-ambitions-ee78af063b415671Pharma Surgeen2026-07-05T22:45:07.000ZEditorial | Independent drug approvals are key to Hong Kong’s biotech ambitionshttps://www.pharmaradar360.com/article/does-crispr-therapeutics-crsp-russell-index-debut-quietly-reframe-its-biotech-gr-87c9577cd0edee75Pharma Surgeen2026-07-05T21:32:18.000ZDoes CRISPR Therapeutics’ (CRSP) Russell Index Debut Quietly Reframe Its Biotech Growth Narrative?https://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-05T19:28:42.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/the-hidden-reason-biotech-breakthroughs-keep-getting-delayed-a4cd1537cb3fbe8bPharma Surgeen2026-07-05T19:05:16.000ZThe Hidden Reason Biotech Breakthroughs Keep Getting Delayedhttps://www.pharmaradar360.com/article/texas-biomed-teams-up-with-uk-based-biotech-company-to-fight-screwworm-87325582fe823f51Pharma Surgeen2026-07-05T19:00:00.000ZTexas Biomed teams up with UK-based biotech company to fight screwwormhttps://www.pharmaradar360.com/article/cmps-stock-rises-23-pre-market-as-compass-achieves-primary-endpoint-in-phase-3-t-4191aa06fc271c3ePharma Surgeen2026-07-05T18:35:53.000ZCMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trialhttps://www.pharmaradar360.com/article/roche-collaborates-with-nurix-therapeutics-to-develop-btk-degrader-bexobrutideg-aecfe63314cca483Pharma Surgeen2026-07-05T18:04:35.000ZRoche collaborates with Nurix Therapeutics to develop BTK degrader bexobrutideg for cancer and immune diseaseshttps://www.pharmaradar360.com/article/meps-supportive-of-draft-biotech-report-but-divisions-over-incentives-remain-fff282b603d604e9Pharma Surgeen2026-07-05T16:21:39.000ZMEPs supportive of draft Biotech report, but divisions over incentives remainhttps://www.pharmaradar360.com/article/ihe-vs-pjp-which-pharmaceutical-etf-is-the-better-buy-for-investors-1688a53a9f740efcPharma Surgeen2026-07-05T16:16:00.000ZIHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?https://www.pharmaradar360.com/article/biotech-stocks-are-surging-in-2026-this-one-stands-out-after-a-pullback-626f44075305061aPharma Surgeen2026-07-05T15:15:00.000ZBiotech Stocks Are Surging in 2026. This One Stands Out After a Pullback.https://www.pharmaradar360.com/article/price-to-sales-forward-of-collegium-pharmaceutical-inc-fwb-354-b43a7e826ec97bddPharma Surgeen2026-07-05T14:42:33.000ZPrice to sales forward of Collegium Pharmaceutical, Inc. – FWB:354https://www.pharmaradar360.com/article/price-to-book-forward-of-china-resources-jiangzhong-pharmaceutical-co-ltd-class-fd4c6270a154603fPharma Surgeen2026-07-05T14:23:21.000ZPrice to book forward of China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A – SSE:600750https://www.pharmaradar360.com/article/roche-reports-positive-phase-3-results-for-divarasib-in-previously-treated-kras-2eabe1a7abcc5efePharma Surgeen2026-07-05T14:15:04.000ZRoche Reports Positive Phase 3 Results for Divarasib in Previously Treated KRAS G12C NSCLChttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-ctt-pharmaceutical-holdings-inc-otc-ctth-81294a0696c4041dPharma Surgeen2026-07-05T14:13:33.000ZPrice to earnings forward of CTT Pharmaceutical Holdings, Inc. – OTC:CTTHhttps://www.pharmaradar360.com/article/maharashtra-fda-flags-three-beauty-creams-over-toxic-mercury-and-lead-levels-42396aaeb2809a02Pharma Surgeen2026-07-05T13:44:23.000ZMaharashtra FDA Flags Three Beauty Creams Over Toxic Mercury and Lead Levelshttps://www.pharmaradar360.com/article/maharashtra-fda-warns-against-three-beauty-creams-after-tests-detect-excessive-m-e18e9f0f5dd43c0dPharma Surgeen2026-07-05T13:39:09.000ZMaharashtra FDA warns against three beauty creams after tests detect excessive mercury, lead levelshttps://www.pharmaradar360.com/article/fidelity-health-care-vs-state-street-biotech-which-etf-fits-your-portfolio-best-911217dff7804f89Pharma Surgeen2026-07-05T13:35:01.000ZFidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?https://www.pharmaradar360.com/article/gni-group-acquires-ayumi-pharmaceutical-for-jpy-44-8-billion-about-276-million-25a51d94eb4252d8Pharma Surgeen2026-07-05T13:22:22.000ZGNI Group Acquires Ayumi Pharmaceutical For JPY 44.8 Billion (About $276 Million)https://www.pharmaradar360.com/article/viatris-vtrs-most-undervalued-nasdaq-stocks-to-buy-right-now-1ceefbec1c56a272Pharma Surgeen2026-07-05T13:18:09.000ZViatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Nowhttps://www.pharmaradar360.com/article/viatris-vtrs-most-undervalued-nasdaq-stocks-to-buy-right-now-0a559e93b03a3f50Pharma Surgeen2026-07-05T13:04:13.000ZViatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Nowhttps://www.pharmaradar360.com/article/ai-is-transforming-drug-discovery-here-is-the-next-trillion-dollar-biotech-oppor-e8a5a156d9d7f02ePharma Surgeen2026-07-05T12:38:22.000ZAI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunityhttps://www.pharmaradar360.com/article/883035-forecast-price-target-prediction-for-2027-0148ec38e640e494Pharma Surgeen2026-07-05T12:15:10.000Z883035 Forecast — Price Target — Prediction for 2027https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-collegium-pharmaceutical-inc-nasdaq-coll-7c3715c36593e325Pharma Surgeen2026-07-05T11:54:16.000ZEnterprise value to revenue forward of Collegium Pharmaceutical, Inc. – NASDAQ:COLLhttps://www.pharmaradar360.com/article/cphi-south-east-asia-2026-to-drive-pharma-partnerships-across-asean-eb53ca0c027965d2Pharma Surgeen2026-07-05T11:22:15.000ZCPHI South East Asia 2026 to drive pharma partnerships across ASEANhttps://www.pharmaradar360.com/article/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-46b2d5c4cbe8b52ePharma Surgeen2026-07-05T10:13:09.000ZUS FDA sends 25 letters to telehealth companies over claims on compounded weight-loss drugshttps://www.pharmaradar360.com/article/needs-to-be-strengthened-maharashtra-food-regulator-chief-on-manpower-8acb00229e1fb6c6Pharma Surgeen2026-07-05T09:52:40.000Z"Needs To Be Strengthened": Maharashtra Food Regulator Chief On Manpowerhttps://www.pharmaradar360.com/article/maharashtra-bans-pak-beauty-cream-with-mercury-lead-level-above-safe-limit-18-wo-5df2982ea5c4f5d6Pharma Surgeen2026-07-05T09:39:09.000ZMaharashtra bans Pak beauty cream with mercury & lead level above safe limit, 18 women fall illhttps://www.pharmaradar360.com/article/price-to-book-forward-of-taiyen-biotech-co-ltd-twse-1737-bfb7d68f69dc114aPharma Surgeen2026-07-05T09:02:15.000ZPrice to book forward of Taiyen Biotech Co. Ltd. – TWSE:1737https://www.pharmaradar360.com/article/biotech-etf-bbc-touches-a-new-52-week-high-652d3bda4c4af155Pharma Surgeen2026-07-05T08:47:38.000ZBiotech ETF (BBC) touches a new 52-week highhttps://www.pharmaradar360.com/article/fjarde-ap-fonden-fourth-swedish-national-pension-fund-boosts-stake-in-teva-pharm-751d7e5541dafe94Pharma Surgeen2026-07-05T08:04:58.000ZFjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stake in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-zhejiang-jolly-pharmaceutical-co-ltd-class-a-szse-3-a512fd742ac9c6d7Pharma Surgeen2026-07-05T07:51:54.000ZPrice to earnings forward of Zhejiang Jolly Pharmaceutical Co., Ltd. Class A – SZSE:300181https://www.pharmaradar360.com/article/zhejiang-huahai-pharmaceutical-sees-h1-net-profit-up-85-95-y-y-321fda51b4ad51f0Pharma Surgeen2026-07-05T07:50:54.000ZZhejiang Huahai Pharmaceutical Sees H1 Net Profit Up 85-95% Y/Yhttps://www.pharmaradar360.com/article/fda-probes-anesthesia-linked-neurological-complications-in-some-patients-of-vene-dfc25dc6a2d21238Pharma Surgeen2026-07-05T07:43:38.000ZFDA probes anesthesia-linked neurological complications in some patients of Venezuelan ancestryhttps://www.pharmaradar360.com/article/video-254-exciting-news-apitegromab-phase-3-trial-updates-raven-johnson-zpfmnqen-1b17109b309287d2Pharma Surgeen2026-07-05T07:42:58.000ZVideo #254 - EXCITING NEWS - Apitegromab Phase 3 Trial Updates Raven Johnson (ZpFMNQeNv4)https://www.pharmaradar360.com/article/gsk-acquires-nuvalent-for-10-6-billion-in-oncology-push-f25e48e82de10623Pharma Surgeen2026-07-05T07:40:42.000ZGSK acquires Nuvalent for $10.6 billion in oncology pushhttps://www.pharmaradar360.com/article/bay-area-biotech-giant-to-lay-off-103-employees-f9672130e758bd10Pharma Surgeen2026-07-05T06:19:31.000ZBay Area biotech giant to lay off 103 employeeshttps://www.pharmaradar360.com/article/kazakhstan-india-strengthen-pharmaceutical-partnership-with-new-investment-push-09aaa4caef287460Pharma Surgeen2026-07-05T06:14:07.000ZKazakhstan, India Strengthen Pharmaceutical Partnership with New Investment Pushhttps://www.pharmaradar360.com/article/residents-in-eastern-congo-cling-to-hope-as-a-new-ebola-treatment-trial-begins-e9ac5afdb17835baPharma Surgeen2026-07-05T06:10:10.000ZResidents in eastern Congo cling to hope as a new Ebola treatment trial beginshttps://www.pharmaradar360.com/article/how-much-could-1-000-invested-in-viking-therapeutics-be-worth-by-2030-80782cf159bd6ca2Pharma Surgeen2026-07-05T06:05:00.000ZHow Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?https://www.pharmaradar360.com/article/price-to-book-forward-of-zhejiang-hisoar-pharmaceutical-co-ltd-class-a-szse-0020-34366910c5b8eb81Pharma Surgeen2026-07-05T05:56:47.000ZPrice to book forward of Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A – SZSE:002099https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-zhejiang-jolly-pharmaceutical-co-ltd-class-a-ad7f0fbe981632e5Pharma Surgeen2026-07-05T05:46:53.000ZEnterprise value to EBIT forward of Zhejiang Jolly Pharmaceutical Co., Ltd. Class A – SZSE:300181https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-shanghai-fosun-pharmaceutical-group-co-lt-05fec87fe0df3d16Pharma Surgeen2026-07-05T05:46:22.000ZEnterprise value to revenue forward of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Class A – SSE:600196https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-touyun-biotech-group-limited-hkex-1332-4aa7e8f9b890045dPharma Surgeen2026-07-05T05:41:23.000ZEnterprise value to EBIT forward of Touyun Biotech Group Limited – HKEX:1332https://www.pharmaradar360.com/article/price-to-sales-forward-of-touyun-biotech-group-limited-hkex-1332-df6f3dd5fa7db0f4Pharma Surgeen2026-07-05T04:50:18.000ZPrice to sales forward of Touyun Biotech Group Limited – HKEX:1332https://www.pharmaradar360.com/article/etfs-investing-in-dizal-pharmaceutical-co-ltd-class-a-stocks-16e98cbd01462d94Pharma Surgeen2026-07-05T04:47:31.000ZETFs Investing in Dizal Pharmaceutical Co Ltd. Class A Stockshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-central-pharmaceutical-jsc-no-3-hnx-dp3-fee30750b4d8dd2fPharma Surgeen2026-07-05T04:28:07.000ZEnterprise value to EBIT forward of Central Pharmaceutical JSC No. 3 – HNX:DP3https://www.pharmaradar360.com/article/price-to-earnings-forward-of-touyun-biotech-group-limited-hkex-1332-dea219fbff458d15Pharma Surgeen2026-07-05T04:19:11.000ZPrice to earnings forward of Touyun Biotech Group Limited – HKEX:1332https://www.pharmaradar360.com/article/psychedelic-nation-psilocybin-treatments-offer-new-hope-for-people-prozac-hasn-t-0325c7264e55ad44Pharma Surgeen2026-07-05T04:01:00.000ZPsychedelic Nation? Psilocybin Treatments Offer New Hope for People Prozac Hasn’t Helpedhttps://www.pharmaradar360.com/article/aribio-accelerates-global-commercialization-of-alzheimers-drug-ar1001-with-strat-8f0afda535f5327dPharma Surgeen2026-07-05T03:48:00.000ZAribio Accelerates Global Commercialization of Alzheimers Drug AR1001 with Strategic Investmenthttps://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-21bc3ca66da6ac95Pharma Surgeen2026-07-05T03:44:08.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-mochida-pharmaceutical-co-ltd-tse-4534-0b6244892d5f65fdPharma Surgeen2026-07-05T03:42:47.000ZEnterprise value to EBIT forward of Mochida Pharmaceutical Co., Ltd. – TSE:4534https://www.pharmaradar360.com/article/soun-stock-rebounds-after-liveperson-deal-retail-bulls-bank-on-ai-opportunity-wi-cc0dbe5068994023Pharma Surgeen2026-07-05T03:30:33.000ZSOUN Stock Rebounds After LivePerson Deal: Retail Bulls Bank On AI Opportunity With Expanded Fortune 100 Client Basehttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-meribank-biotech-co-ltd-tpex-4724-9e40e66f7e73afc0Pharma Surgeen2026-07-05T03:27:10.000ZEnterprise value to EBIT forward of Meribank Biotech Co Ltd – TPEX:4724https://www.pharmaradar360.com/article/existing-drug-could-speed-new-treatment-for-rare-liver-cancer-7f47aa32206892f8Pharma Surgeen2026-07-05T03:19:36.000ZExisting drug could speed new treatment for rare liver cancerhttps://www.pharmaradar360.com/article/biib-stock-ends-3-higher-why-this-strategist-picks-biogen-over-other-biotech-pee-c961ecccbe965512Pharma Surgeen2026-07-05T03:17:03.000ZBIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peershttps://www.pharmaradar360.com/article/price-to-sales-forward-of-mochida-pharmaceutical-co-ltd-fwb-mfy-d89dbad90d8be7c1Pharma Surgeen2026-07-05T02:49:31.000ZPrice to sales forward of Mochida Pharmaceutical Co., Ltd. – FWB:MFYhttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-group-sehk-3692-wins-trial-approval-is-it-fully-priced-a1a14f4cafae801bPharma Surgeen2026-07-05T02:42:53.000ZHansoh Pharmaceutical Group (SEHK:3692) Wins Trial Approval, Is It Fully Priced?https://www.pharmaradar360.com/article/price-to-earnings-forward-of-mochida-pharmaceutical-co-ltd-fwb-mfy-d81c9163bc32c267Pharma Surgeen2026-07-05T02:28:03.000ZPrice to earnings forward of Mochida Pharmaceutical Co., Ltd. – FWB:MFYhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-mochida-pharmaceutical-co-ltd-fwb-mfy-ba3ce367234ca90bPharma Surgeen2026-07-05T02:23:57.000ZEnterprise value to revenue forward of Mochida Pharmaceutical Co., Ltd. – FWB:MFYhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-tiansheng-pharmaceutical-group-co-ltd-class-a-szse-002-734f9ed55c153186Pharma Surgeen2026-07-05T02:22:40.000ZPrice to sales forward of Tiansheng Pharmaceutical Group Co. Ltd. Class A – SZSE:002872https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-agimexpharm-pharmaceutical-joint-stock-co-dd1d4eb0a7457c13Pharma Surgeen2026-07-05T02:07:46.000ZEnterprise value to EBITDA forward of Agimexpharm Pharmaceutical Joint Stock Co – UPCOM:AGPhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-taiyen-biotech-co-ltd-twse-1737-f2fbe5be5932109fPharma Surgeen2026-07-05T02:03:36.000ZEnterprise value to revenue forward of Taiyen Biotech Co. Ltd. – TWSE:1737https://www.pharmaradar360.com/article/shaanxi-micot-pharmaceutical-technology-co-ltd-class-h-revenue-breakdown-hkex-23-ebaed7eae05596bePharma Surgeen2026-07-05T02:03:24.000ZShaanxi Micot Pharmaceutical Technology Co., Ltd. Class H Revenue Breakdown – HKEX:2335https://www.pharmaradar360.com/article/world-automated-patch-clamp-system-market-analysis-forecast-size-trends-and-insi-4d37a651940767cfPharma Surgeen2026-07-05T02:01:05.000ZWorld Automated Patch Clamp System - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/daily-brief-thematic-sector-industry-apac-healthcare-weekly-july-5-cspc-and-more-0d84d27130f13c68Pharma Surgeen2026-07-05T02:00:55.000ZDaily Brief Thematic (Sector/Industry): APAC Healthcare Weekly (July 5) – CSPC and morehttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-taiyen-biotech-co-ltd-twse-1737-8ac3a0321265246cPharma Surgeen2026-07-05T02:00:36.000ZPrice to earnings forward of Taiyen Biotech Co. Ltd. – TWSE:1737https://www.pharmaradar360.com/article/price-to-sales-forward-of-great-novel-therapeutics-biotech-medicals-corp-tpex-74-0bf51be9aba16ad4Pharma Surgeen2026-07-05T01:46:54.000ZPrice to sales forward of Great Novel Therapeutics Biotech & Medicals Corp. – TPEX:7427https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-agimexpharm-pharmaceutical-joint-stock-co-up-939f0aaaa180185ePharma Surgeen2026-07-05T01:33:01.000ZEnterprise value to EBIT forward of Agimexpharm Pharmaceutical Joint Stock Co – UPCOM:AGPhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-zhejiang-jolly-pharmaceutical-co-ltd-clas-7d86908e02257244Pharma Surgeen2026-07-05T01:26:28.000ZEnterprise value to revenue forward of Zhejiang Jolly Pharmaceutical Co., Ltd. Class A – SZSE:300181https://www.pharmaradar360.com/article/veraxa-biotech-vrxa-stock-price-news-analysis-2b09819439ca80fePharma Surgeen2026-07-05T01:25:37.000ZVeraxa Biotech (VRXA) Stock Price, News & Analysishttps://www.pharmaradar360.com/article/apac-healthcare-weekly-july-5-cspc-abbisko-insilico-takeda-nippon-shinyaku-otsuk-16b5226e55398fe9Pharma Surgeen2026-07-05T00:49:00.000ZAPAC Healthcare Weekly (July 5) – CSPC, Abbisko, Insilico, Takeda, Nippon Shinyaku, Otsuka, CSLhttps://www.pharmaradar360.com/article/new-chongqing-institute-aims-to-turn-biotech-research-into-commercial-products-2f2d6d9183e28d01Pharma Surgeen2026-07-05T00:41:52.000ZNew Chongqing Institute Aims to Turn Biotech Research into Commercial Productshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-taiyen-biotech-co-ltd-twse-1737-67914b1b7891bc39Pharma Surgeen2026-07-05T00:39:21.000ZPrice to sales forward of Taiyen Biotech Co. Ltd. – TWSE:1737https://www.pharmaradar360.com/article/price-to-earnings-forward-of-agimexpharm-pharmaceutical-joint-stock-co-upcom-agp-520990e808b49809Pharma Surgeen2026-07-05T00:25:24.000ZPrice to earnings forward of Agimexpharm Pharmaceutical Joint Stock Co – UPCOM:AGPhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-hunan-hansen-pharmaceutical-co-ltd-class-a-szse-002-9b62456478e43a07Pharma Surgeen2026-07-05T00:07:54.000ZPrice to earnings forward of Hunan Hansen Pharmaceutical Co., Ltd. Class A – SZSE:002412https://www.pharmaradar360.com/article/three-dimensional-preoperative-planning-in-reverse-shoulder-arthroplasty-a-syste-2227248f6d5debe2Pharma Surgeen2026-07-05T00:00:00.000ZThree-Dimensional Preoperative Planning in Reverse Shoulder Arthroplasty: A Systematic Review of Implant Positioning Accuracy and Clinical Outcomeshttps://www.pharmaradar360.com/article/metabolomic-biomarkers-for-the-early-detection-of-infectious-diseases-a-systemat-69d6991b5da081eaPharma Surgeen2026-07-05T00:00:00.000ZMetabolomic Biomarkers for the Early Detection of Infectious Diseases: A Systematic Review and Meta-Analysis of Diagnostic Performance and Clinical Utilityhttps://www.pharmaradar360.com/article/colistin-resistance-in-klebsiella-pneumoniae-mechanisms-detection-and-clinical-i-e590b55b2ab5e6abPharma Surgeen2026-07-05T00:00:00.000ZColistin Resistance in Klebsiella pneumoniae: Mechanisms, Detection, and Clinical Impacthttps://www.pharmaradar360.com/article/construction-and-effectiveness-study-of-a-marketing-excellence-system-for-multin-fff6340ef8ff2dffPharma Surgeen2026-07-05T00:00:00.000ZConstruction and Effectiveness Study of a Marketing Excellence System for Multinational Pharmaceutical Companies Under the Dual Drive of Compliance and Digitalizationhttps://www.pharmaradar360.com/article/efficacy-and-schedule-of-ivermectin-in-vivo-against-naturally-acquired-infestati-180aeb530ad71199Pharma Surgeen2026-07-05T00:00:00.000ZEfficacy and schedule of Ivermectin in vivo against naturally acquired infestation of Sarcoptes scabiei on wild red foxes (Vulpes vulpes) treated in a controlled veterinary / clinical rehabilitation environmenthttps://www.pharmaradar360.com/article/clinical-recovery-from-multidrug-resistant-bacterial-infection-in-a-suppurative-dc48dcde53c65b24Pharma Surgeen2026-07-05T00:00:00.000ZClinical recovery from multidrug-resistant bacterial infection in a suppurative wound of a Royal Bengal Tiger using linezolidhttps://www.pharmaradar360.com/article/long-term-clinical-effectiveness-of-early-versus-late-orthodontic-intervention-0759099071e41971Pharma Surgeen2026-07-05T00:00:00.000ZLong-term Clinical Effectiveness of Early Versus Late Orthodontic Interventionhttps://www.pharmaradar360.com/article/ethical-considerations-in-clinical-research-in-prasuti-tantra-and-stree-roga-a-c-b445018338847514Pharma Surgeen2026-07-05T00:00:00.000ZEthical Considerations in Clinical Research in Prasuti Tantra and Stree Roga: A Comprehensive Review of Ayurvedic Interventions During Pregnancy and Women's Reproductive Healthhttps://www.pharmaradar360.com/article/tetrahydropyrimidine-5-carboxylate-attenuates-experimentally-induced-inflammatio-218d281fd237d7b6Pharma Surgeen2026-07-05T00:00:00.000ZTetrahydropyrimidine-5-carboxylate attenuates experimentally induced inflammation through regulation of inflammatory and oxidative stress biomarkers in Wistar ratshttps://www.pharmaradar360.com/article/population-pharmacokinetics-of-piperacillin-in-non-critically-ill-hospitalized-p-fecfa1537b8dd0fePharma Surgeen2026-07-05T00:00:00.000ZPopulation pharmacokinetics of piperacillin in non-critically Ill hospitalized patients: A study from Pakistanhttps://www.pharmaradar360.com/article/dynamic-evolution-prediction-and-patient-stratification-of-chemotherapy-induced-0c40c80095b3963cPharma Surgeen2026-07-05T00:00:00.000ZDynamic evolution, prediction and patient stratification of chemotherapy-induced neutropenia in a predominantly breast cancer cohort: A decision-support study for building a bundle care strategyhttps://www.pharmaradar360.com/article/effects-of-levofloxacin-eye-drops-on-ocular-surface-bacterial-colonization-and-p-8169288b67b621d5Pharma Surgeen2026-07-05T00:00:00.000ZEffects of levofloxacin eye drops on ocular surface bacterial colonization and postoperative infection rate in patients undergoing blepharoplasthttps://www.pharmaradar360.com/article/the-metabolic-blind-spot-bridging-the-gap-between-clinical-medicine-and-nutritio-6498e6f76cf5b9c8Pharma Surgeen2026-07-05T00:00:00.000ZThe Metabolic Blind Spot: Bridging the Gap between Clinical Medicine and Nutritional Sciencehttps://www.pharmaradar360.com/article/resurgence-of-influenza-following-the-lifting-of-non-pharmaceutical-intervention-1feb58d86bdb1f07Pharma Surgeen2026-07-05T00:00:00.000ZResurgence of Influenza Following the Lifting of Non-pharmaceutical Interventions in Shenzhen, Chinahttps://www.pharmaradar360.com/article/latent-profiles-of-teaching-self-efficacy-and-clinical-teaching-behaviors-among-a45d8d50eb5e14c3Pharma Surgeen2026-07-05T00:00:00.000ZLatent Profiles of Teaching Self-Efficacy and Clinical Teaching Behaviors Among Clinical Nurse Preceptors and Factors Associated With Profile Membership: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/talking-with-the-book-not-just-at-children-a-cluster-randomized-trial-of-dialogi-af9a8f82f1c8bb04Pharma Surgeen2026-07-05T00:00:00.000ZTalking With the Book, Not Just at Children: A Cluster-Randomized Trial of Dialogic Reading in Luganda Primary 1 Classroomshttps://www.pharmaradar360.com/article/the-effects-of-cash-transfers-subsidized-childcare-and-life-skills-training-on-a-1c9639dfda4a82daPharma Surgeen2026-07-05T00:00:00.000ZThe effects of cash transfers, subsidized childcare, and life skills training on adolescent mothers' participation in school or vocational training in Malawi: evidence from the PROMOTE project pilot randomized controlled trialhttps://www.pharmaradar360.com/article/reliability-and-clinical-accuracy-of-chatgpt-in-post-fess-counselling-a-multi-re-e0c4351f790d7074Pharma Surgeen2026-07-05T00:00:00.000ZReliability and Clinical Accuracy of ChatGPT in Post-FESS Counselling: A Multi-Reviewer Evaluation.https://www.pharmaradar360.com/article/clinical-validation-of-orthodontic-oral-health-literacy-and-behavior-tools-ohl-o-c820888afa489500Pharma Surgeen2026-07-05T00:00:00.000ZClinical Validation of Orthodontic Oral Health Literacy and Behavior Tools (OHL-Ortho &amp;amp; OHB): A Cross-Sectional Assessment Using CPITN, OHI-S and Objective Knowledge Measureshttps://www.pharmaradar360.com/article/nail-biting-in-children-with-adhd-exploring-its-clinical-correlates-psychiatric-d1e553430d2807c3Pharma Surgeen2026-07-05T00:00:00.000ZNail Biting in Children With ADHD: Exploring Its Clinical Correlates, Psychiatric Comorbidities and Association With Other Body-focused Repetitive Behaviorshttps://www.pharmaradar360.com/article/maternal-risk-factors-and-short-term-clinical-outcomes-of-different-small-vulner-b5d1424311324a16Pharma Surgeen2026-07-05T00:00:00.000ZMaternal Risk Factors and Short-Term Clinical Outcomes of Different Small Vulnerable Newborn (SVN) Phenotypes: A Retrospective Cohort Study of 998 Caseshttps://www.pharmaradar360.com/article/generosity-access-frictions-and-the-win-win-region-in-pharmaceutical-markets-995e3f132956123fPharma Surgeen2026-07-05T00:00:00.000ZGenerosity, Access Frictions, and the Win–Win Region in Pharmaceutical Markets (*)https://www.pharmaradar360.com/article/understanding-eating-behaviors-in-obesity-a-debq-based-analysis-of-clinical-and-be9c348c0db124d4Pharma Surgeen2026-07-05T00:00:00.000ZUnderstanding eating behaviors in obesity: a DEBQ-based analysis of clinical and demographic factorshttps://www.pharmaradar360.com/article/sequential-anaphylaxis-and-delayed-rituximab-induced-serum-sickness-with-skin-te-f47f0dee0bd8c959Pharma Surgeen2026-07-05T00:00:00.000ZSequential anaphylaxis and delayed rituximab-induced serum sickness with skin testing findings: a case reporthttps://www.pharmaradar360.com/article/tca-controlled-histone-succinylation-identifies-idh3b-as-a-prognostic-and-therap-b38d08b3300727d1Pharma Surgeen2026-07-05T00:00:00.000ZTCA-controlled histone succinylation identifies IDH3B as a prognostic and therapeutic target in AMLhttps://www.pharmaradar360.com/article/the-roles-and-clinical-significance-of-linc01140-in-human-cancers-in-the-real-wo-4e34630e005b3c55Pharma Surgeen2026-07-05T00:00:00.000ZThe roles and clinical significance of LINC01140 in human cancers in the real worldhttps://www.pharmaradar360.com/article/proteomic-and-glycosylation-biomarkers-in-rheumatoid-arthritis-advancing-early-d-e752107dfea5f6f6Pharma Surgeen2026-07-05T00:00:00.000ZProteomic and glycosylation biomarkers in rheumatoid arthritis: advancing early diagnosis and precision therapyhttps://www.pharmaradar360.com/article/beyond-biomechanics-advancing-physical-therapy-through-bioenergetic-integration-9f87b74dbdb53bc3Pharma Surgeen2026-07-05T00:00:00.000ZBeyond Biomechanics: Advancing Physical Therapy through Bioenergetic Integration in Clinical Practicehttps://www.pharmaradar360.com/article/a-novel-te-ethosomes-loaded-thermosensitive-gel-for-enhanced-transdermal-deliver-472d0ca298a8f746Pharma Surgeen2026-07-05T00:00:00.000ZA Novel Te-Ethosomes-loaded Thermosensitive Gel for Enhanced Transdermal Delivery and Melasma Therapyhttps://www.pharmaradar360.com/article/tinnitus-hyperacusis-and-somatic-complaints-in-a-diverse-norwegian-clinical-popu-f15a597abf9d3466Pharma Surgeen2026-07-05T00:00:00.000ZTinnitus, hyperacusis and somatic complaints in a diverse Norwegian clinical population: implications for assessment and rehabilitationhttps://www.pharmaradar360.com/article/impact-of-standardized-interdisciplinary-nursing-protocols-on-clinical-outcomes-386c1b012e7880b7Pharma Surgeen2026-07-05T00:00:00.000ZImpact of standardized interdisciplinary nursing protocols on clinical outcomes in neurosurgical patients undergoing craniomaxillofacial reconstruction: a multicenter retrospective studyhttps://www.pharmaradar360.com/article/a-unified-molecular-graph-and-protein-language-model-framework-for-predicting-hu-350a188446e1f2dfPharma Surgeen2026-07-05T00:00:00.000ZA Unified Molecular Graph and Protein Language Model Framework for Predicting Human Drug–Hormone Receptor Interactions with Structure-Aware Validationhttps://www.pharmaradar360.com/article/advancing-biochemical-molecule-registration-representation-and-search-for-new-dr-880d786368d1f786Pharma Surgeen2026-07-05T00:00:00.000ZAdvancing Biochemical Molecule Registration, Representation and Search for New Drug Modalitieshttps://www.pharmaradar360.com/article/unsupervised-image-classification-with-patch-shared-hierarchical-som-on-mnist-an-6467c5233ede6b99Pharma Surgeen2026-07-05T00:00:00.000ZUnsupervised image classification with patch shared hierarchical SOM on MNIST and for clinical blastocyst quality assessmenthttps://www.pharmaradar360.com/article/a-comprehensive-review-of-efficient-deep-learning-for-clinical-medical-imaging-d-661f0cdbfc301881Pharma Surgeen2026-07-05T00:00:00.000ZA comprehensive review of efficient deep learning for clinical medical imaging deploymenthttps://www.pharmaradar360.com/article/effects-of-osteostrong-vs-dynamic-multicomponent-exercise-on-physical-function-i-e632925614f53eabPharma Surgeen2026-07-05T00:00:00.000ZEffects of OsteoStrong vs. dynamic multicomponent exercise on physical function in older women in the BONEMORE randomized controlled trialhttps://www.pharmaradar360.com/article/concordance-between-multidisciplinary-tumor-board-decisions-and-ai-based-recomme-4c2f0737ccb14252Pharma Surgeen2026-07-05T00:00:00.000ZConcordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomeshttps://www.pharmaradar360.com/article/transformers-for-3d-medical-image-analysis-a-systematic-review-of-architectural-05b63c7510d8d2bbPharma Surgeen2026-07-05T00:00:00.000ZTransformers for 3D medical image analysis: a systematic review of architectural innovations, performance, and clinical applicationshttps://www.pharmaradar360.com/article/clonal-dynamic-changes-during-the-progression-of-myelodysplastic-neoplasms-to-se-c902c9c15e14743ePharma Surgeen2026-07-05T00:00:00.000ZClonal dynamic changes during the progression of myelodysplastic neoplasms to secondary acute myeloid leukemia: a paired-sample comparisonhttps://www.pharmaradar360.com/article/tfe3-rearranged-pecoma-with-hepatic-and-pulmonary-involvement-diagnostic-challen-9875f80902894fe4Pharma Surgeen2026-07-05T00:00:00.000ZTFE3-rearranged PEComa with hepatic and pulmonary involvement: diagnostic challenges and resistance to mTOR-targeted therapyhttps://www.pharmaradar360.com/article/editorial-for-effect-of-visualized-respiratory-training-on-patient-cooperation-a-c072c60507380bb0Pharma Surgeen2026-07-05T00:00:00.000ZEditorial for “Effect of Visualized Respiratory Training on Patient Cooperation and Image Quality in Gadoxetic Acid Disodium‐Enhanced Liver <scp>MRI</scp> : A Randomized Controlled Trial”https://www.pharmaradar360.com/article/scp-sflt-scp-1-scp-plgf-scp-ratio-in-the-diagnosis-of-preeclampsia-on-the-scp-ma-adbac078ec766912Pharma Surgeen2026-07-05T00:00:00.000Z<scp>sFlt</scp> ‐1/ <scp>PlGF</scp> Ratio in the Diagnosis of Preeclampsia on the <scp>MAGLUMI X3</scp> Analyzerhttps://www.pharmaradar360.com/article/application-of-cell-free-scp-dna-scp-barcode-enabled-single-molecule-test-for-no-7cd0666af489dc1ePharma Surgeen2026-07-05T00:00:00.000ZApplication of Cell‐Free <scp>DNA</scp> Barcode‐Enabled Single‐Molecule Test for Non‐Invasive Prenatal Testing of α‐Thalassemia and β‐Thalassemiahttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-dong-nai-pharmaceutical-joint-stock-co-upcom-58ab195e03195fd6Pharma Surgeen2026-07-04T23:57:22.000ZEnterprise value to EBIT forward of Dong Nai Pharmaceutical Joint Stock Co – UPCOM:DPPhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hanmi-pharmaceutical-co-ltd-krx-128940-3faa757aa0f62350Pharma Surgeen2026-07-04T23:55:21.000ZEnterprise value to EBIT forward of Hanmi Pharmaceutical Co., Ltd. – KRX:128940https://www.pharmaradar360.com/article/capricor-sinks-after-fda-rejects-drug-for-muscle-disease-82a1a89de593fe0ePharma Surgeen2026-07-04T23:54:13.000ZCapricor Sinks After FDA Rejects Drug for Muscle Disease